ArticlePloS one2026
Validation and evaluation of diagnostic tests for Schistosoma mansoni in Brazil: The ValidaXisto study protocol.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The persistence of schistosomiasis as a serious public health problem can be attributed, in part, to the lack of more accurate diagnostic techniques, particularly in areas with low prevalence and low parasitic burden. Thus, an effective diagnostic tool with broad applicability for detecting active infections in both high- and low-prevalence settings, as well as for accurately monitoring cure after therapeutic interventions, represent an instrument of utmost importance for controlling disease transmission. Therefore, we propose evaluating different commercial tests for schistosomiasis diagnosis identified through a review of all tests registered to be used in Brazil by the Brazilian regulatory agency (ANVISA) and those registered by other regulatory agencies, as well as prototypes of tests under development. In addition, we propose the development and evaluation of molecular diagnostic methodologies for schistosomiasis using different biological samples (stool, blood, and urine) from individuals living in an endemic area. The Kato-Katz technique, with 18 slides per stool sample, will be used as the reference test for definition of schistosomiasis cases. The performance of the evaluated techniques will be compared with respect to sensitivity, specificity, accuracy, positive and negative likelihood ratios, agreement with the reference test, cost, time, and ease of execution. The effectiveness and feasibility of these diagnostic tests will be assessed to recommend their incorporation into the schistosomiasis surveillance actions of the Ministry of Health within the Brazilian Unified Health System (SUS) in the short to medium term, considering the conditions faced by surveillance programs within Primary Health Care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.